Comparative Efficacy of Secukinumab versus Tumor Necrosis Factor Inhibitors for the Treatment of Takayasu's Arteritis.
Xinping TianMeng Tao LiNan JiangYang ZhaoJing LiYangzhong ZhouYahong WangYing WangTaotao LiYunjiao YangYanhong WangPeter A MerkelXiao-Feng ZengPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
These results suggest that secukinumab and TNFi are effective for patients with TAK who failed to respond to oral glucocorticoids and conventional immunosuppressive agents, with similar response rates at 3 and 6 months.